Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Pelthos Therapeutics Inc.AMEX: PTHS
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 28860.4% from a year ago
Net receivables stood at $11.7M at the end of Q1 FY2026, up 28860.4% from a year earlier and up 32.1% from the prior quarter.
Context
- Net receivables amounted to 8.0% of total assets at the end of Q1 FY2026, up 3.6 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +28860.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 8.86M USD
- Year-over-year change
- +21825.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.86M | +21825.7% |
| FY2024 | 2024-12-31 | 40.4K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 net receivables of $11.7M is the highest of the 4 companies compared; the peer median is $53.94K.
- Its year-over-year change of +28860.4% is the highest of 3, against a peer median of -26.1%.
- Net receivables amounts to 8.0% of total assets for PTHS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $11.7M | +28860.4% | — | 8.0% | |
| Dec 2025 | $235K | -82.0% | -28.7% | 0.0% | |
| Mar 2026 | $53.94K | +29.7% | -67.5% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PTHS) | $53.94K | -26.1% | -48.1% | 0.0% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.